Contents
Vol 6, Issue 221
Contents
Editorial
- Turning the Titanic
The R&D engine must be redirected toward deciphering the natural histories of human diseases and using this knowledge to select therapeutic targets.
Focus
- Right Answers, Wrong Questions in Clinical Research
To ensure that clinical research arrives at the “right” answers to the right questions for patients, studies should be designed to more closely approximate real-world use of therapeutics and devices.
Research Articles
- Intramuscular Therapeutic Vaccination Targeting HPV16 Induces T Cell Responses That Localize in Mucosal Lesions
T helper 1 (TH1) immune responses are detectable in target lesions after therapeutic vaccination.
- Bioengineering Dermo-Epidermal Skin Grafts with Blood and Lymphatic Capillaries
Human lymphatic capillaries were engineered in a 3D hydrogel system to improve dermo-epidermal skin grafting.
- Antioxidants Accelerate Lung Cancer Progression in Mice
The antioxidants acetylcysteine and vitamin E accelerate tumor progression and reduce survival in mouse models of lung cancer by disrupting the ROS-p53 axis.
Editors' Choice
- Regenerative Medicine Gets Vocal
An acellular scaffold derived from urinary bladder extracellular matrix is able to regenerate a functional larynx.
- TRAIL-Blazing Therapy Against Circulating Tumor Cells
Nanoparticle-mediated functionalization of leukocytes is effective against circulating tumor cells.
- A Simple Solution for a Big Problem
A randomized controlled trial shows improved gut villous morphology in patients with environmentally induced enteropathy given high-dose micronutrient supplements.
- Moving from Unknown Unknown to Known Unknown
Genomic analysis of nearly 5000 tumors demonstrates that we are far from finding all the cancer genes.
- Shiva the Destroyer: Targeting the Destruction of RNA Polymerase for Cancer Treatment
A new drug with a unique mechanism of action intercalates into GC-rich ribosomal DNA, blocking RNA polymerase I and inhibiting tumor growth.
- “It’s ARAP” for Type II Diabetes
Increased ARAP1 expression is a risk factor for type II diabetes.
